Reported about 1 month ago
Jiangsu Hengrui Pharmaceuticals Co. is considering a second stock listing in Hong Kong potentially as soon as next year, with expected proceeds of at least $2 billion. Shares traded in Shanghai rose 12% this year but dipped 5.7% following news of the prospective listing, which seeks to navigate fundraising challenges in mainland China. The company, which went public in Shanghai in 2000, holds over 580 patents in China and globally and employs approximately 20,000 staff.
Source: YAHOO